A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

被引：2
|
作者：
Sochacki, Andrew L. [1 ]
Burger, Jan A. [2 ]
Ludwig, Carrianne [3 ]
Assaily, Wissam [3 ]
Munasinghe, Wijith [3 ]
Pappano, William [3 ]
Greenberg, Edward [3 ]
Will, Christine [3 ]
Thompson, Meghan C. [4 ]
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181671
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Mosunetuzumab Retreatment is Effective and WellTolerated in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
    Cheah, Chan Yoon
    Nancy, Bartlett L.
    Sarit, Assouline E.
    Stephen, Schuster J.
    Kim, Won Seog
    Shadman, Mazyar
    Isufi, Iris
    Yin Shen
    Michelle, Doral Y.
    Sit, Jason
    Chen, Vivian
    Huang Huang
    Zhou Mingzhu
    Michael, Wei C.
    Budde, L. Elizabeth
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S44 - S45
  • [22] POPULATION PHARMACOKIN ETICS OF ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
    Padros, M. Bravo
    Conrado, D.
    Zhu, M.
    Srinivasan, K.
    Meng, X.
    Yan, H.
    Davis, J.
    Harnisch, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
  • [23] Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Uchida, Toshiki
    Suzuki, Tatsuya
    Kobayashi, Yukio
    Mori, Masakazu
    Terui, Yasuhito
    Yokoyama, Masahiro
    Hotta, Tomomitsu
    CANCER SCIENCE, 2013, 104 (01) : 105 - 110
  • [24] Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth A.
    Kuruvilla, John G.
    Smith, Sonali M.
    Porcu, Pierluigi
    Maddocks, Kami J.
    Ruppert, Amy S.
    Byrd, John C.
    Grever, Michael R.
    Blum, Kristie A.
    BLOOD, 2015, 126 (23)
  • [25] Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ogura, Michinori
    Uchida, Toshiki
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Watanabe, Takashi
    Kasai, Masanobu
    Matsumoto, Yosuke
    Shimizu, Daisuke
    Ogawa, Yoshiaki
    Ohmachi, Ken
    Yokoyama, Hiroki
    Tobinai, Kensei
    CANCER SCIENCE, 2010, 101 (09) : 2054 - 2058
  • [26] First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas - Preliminary Results
    Maruyama, Dai
    Tobinai, Kensei
    Makita, Shinichi
    Ishida, Takashi
    Kusumoto, Shigeru
    Ishitsuka, Kenji
    Yoshimitsu, Makoto
    Imaizumi, Yoshitaka
    Sawayama, Yasushi
    Takeuchi, Shogo
    Utsunomiya, Atae
    Tsukasaki, Kunihiro
    Fujitani, Sumiaki
    Araki, Kazushi
    BLOOD, 2017, 130
  • [27] A phase I, first-in-human study of ONO-7018 in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.
    Byrd, John C.
    Porcu, Pierluigi
    Sundermeier, Thomas
    Nakada, Takashi
    Iwata, Takeyuki
    Prados, Sergio
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma
    Michot, Jean-Marie
    Bouabdallah, Reda
    Doorduijn, Jeanette K.
    Boccomini, Carola
    Kersten, Marie Jose
    Chiappella, Annalisa
    Zinzani, Pier Luigi
    Salles, Gilles
    Bijou, Fontanet
    Hentrup, Mei
    Rhee, So Hyun
    Hagner, Patrick
    Klein, Christian
    Pourdehnad, Michael
    Hege, Kristen
    Dobmeyer, Juergen
    Nikolova, Zariana
    Ribrag, Vincent
    BLOOD, 2020, 136
  • [29] Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma
    Barr, Paul M.
    Smith, Stephen
    Roschewski, Mark
    O'Brien, Susan M.
    Sharman, Jeff P.
    Melear, Jason M.
    Patel, Priti
    Calvo, Roser
    Yang, Helen
    Spurgeon, Stephen
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1728 - 1732
  • [30] First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
    Hamilton, Erika P.
    Wang, Judy S.
    Oza, Amit M.
    Patel, Manish R.
    Ulahannan, Susanna V.
    Bauer, Todd
    Karlix, Janet L.
    Zeron-Medina, Jorge
    Fabbri, Giulia
    Marco-Casanova, Paola
    Moorthy, Ganesh
    Hattersley, Maureen M.
    Littlewood, Gillian M.
    Mitchell, Patrick
    Saeh, Jamal
    Pouliot, Gayle P.
    Moore, Kathleen N.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (10) : 1154 - 1165
12345